Several studies have explored the therapeutic targeting of CEACAM6 in various cancers using immunotherapeutic agents such as immunotoxin-based therapy36, monoclonal antibodies6, anti-CEACAM6 single chain variable fragment37, and antibody-drug conjugates38. The gene discussed is CEACAM6; the disease is cancer.